These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 1587291)

  • 1. Post-menopausal breast cancer risk: oral estrogen treatment and abdominal obesity induce opposite changes in possibly important biological variables.
    Campagnoli C; Biglia N; Belforte P; Botta D; Pedrini E; Sismondi P
    Eur J Gynaecol Oncol; 1992; 13(2):139-54. PubMed ID: 1587291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conjugated estrogens and breast cancer risk.
    Campagnoli C; Ambroggio S; Biglia N; Sismondi P
    Gynecol Endocrinol; 1999 Dec; 13 Suppl 6():13-9. PubMed ID: 10862264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential impact on breast cancer risk of circulating insulin-like growth factor I modifications induced by oral HRT in menopause.
    Campagnoli C; Biglia N; Peris C; Sismondi P
    Gynecol Endocrinol; 1995 Mar; 9(1):67-74. PubMed ID: 7793303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of oral conjugated estrogens and transdermal estradiol on insulin-like growth factor 1, growth hormone and sex hormone binding globulin serum levels.
    Campagnoli C; Biglia N; Altare F; Lanza MG; Lesca L; Cantamessa C; Peris C; Fiorucci GC; Sismondi P
    Gynecol Endocrinol; 1993 Dec; 7(4):251-8. PubMed ID: 8147234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HRT and breast cancer risk: a clue for interpreting the available data.
    Campagnoli C; Biglia N; Cantamessa C; Lesca L; Sismondi P
    Maturitas; 1999 Dec; 33(3):185-90. PubMed ID: 10656496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgenic progestogens oppose the decrease of insulin-like growth factor I serum level induced by conjugated oestrogens in postmenopausal women. Preliminary report.
    Campagnoli C; Biglia N; Lanza MG; Lesca L; Peris C; Sismondi P
    Maturitas; 1994 May; 19(1):25-31. PubMed ID: 7935029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormone replacement therapy and cancer.
    Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer and hormone replacement therapy: putting the risk into perspective.
    Campagnoli C; Abbà C; Ambroggio S; Biglia N; Ponzone R
    Gynecol Endocrinol; 2001 Dec; 15 Suppl 6():53-60. PubMed ID: 12227887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
    Genazzani AR; Gadducci A; Gambacciani M
    Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of hormonal replacement therapy on plasma sex hormone-binding globulin, androgen and insulin-like growth factor-1 levels in postmenopausal women.
    Stomati M; Hartmann B; Spinetti A; Mailand D; Rubino S; Albrecht A; Huber J; Petraglia F; Genazzani AR
    J Endocrinol Invest; 1996 Sep; 19(8):535-41. PubMed ID: 8905477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patients.
    Lønning PE; Helle SI; Johannessen DC; Adlercreutz H; Lien EA; Tally M; Ekse D; Fotsis T; Anker GB; Hall K
    Clin Endocrinol (Oxf); 1995 Jan; 42(1):23-30. PubMed ID: 7534218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral 17beta-estradiol and sequential progesterone in menopause: effects on insulin-like growth factors and their binding proteins.
    Mozzanega B; Babbo GL; Salmaso L; De Toni R; Schiavo A; Mioni R; de Kreutzenberg SV
    Gynecol Endocrinol; 2007 Jan; 23(1):50-7. PubMed ID: 17484513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A two-by-two factorial trial comparing oral with transdermal estrogen therapy and fenretinide with placebo on breast cancer biomarkers.
    Decensi A; Bonanni B; Baglietto L; Guerrieri-Gonzaga A; Ramazzotto F; Johansson H; Robertson C; Marinucci I; Mariette F; Sandri MT; Daldoss C; Bianco V; Buttarelli M; Cazzaniga M; Franchi D; Cassano E; Omodei U
    Clin Cancer Res; 2004 Jul; 10(13):4389-97. PubMed ID: 15240527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effects of continuous oral and transdermal estrogen replacement therapy on sex hormone binding globulin and free testosterone levels.
    Serin IS; Ozçelik B; Başbuğ M; Aygen E; Kula M; Erez R
    Eur J Obstet Gynecol Reprod Biol; 2001 Dec; 99(2):222-5. PubMed ID: 11788176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of various progestogens on metabolic risk factors for breast cancer.
    Campagnoli C; Abbà C; Ambroggio S; Lotano MR; Peris C
    Gynecol Endocrinol; 2007 Oct; 23 Suppl 1():22-31. PubMed ID: 17943536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of bilateral ovariectomy and estrogen replacement therapy on serum leptin, sex hormone binding globulin and insulin like growth factor-I levels.
    Nar A; Demirtas E; Ayhan A; Gurlek A
    Gynecol Endocrinol; 2009 Dec; 25(12):773-8. PubMed ID: 19905995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of hormone replacement therapy on insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-1 to IGFBP-4: implications for cardiovascular risk.
    Heald A; Kaushal K; Anderson S; Redpath M; Durrington PN; Selby PL; Gibson MJ
    Gynecol Endocrinol; 2005 Mar; 20(3):176-82. PubMed ID: 16019358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation by progestogens of the effects of oestrogen on hepatic endocrine function in postmenopausal women.
    Nugent AG; Leung KC; Sullivan D; Reutens AT; Ho KK
    Clin Endocrinol (Oxf); 2003 Dec; 59(6):690-8. PubMed ID: 14974909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conjugated estrogen/progestagen versus tibolone hormone replacement therapy in postmenopausal women: Effects on carbohydrate metabolism and serum sex hormone-binding globulin.
    Odmark IS; Carlström K; Jonsson B; Jonasson AF
    Maturitas; 2006 Jan; 53(1):89-96. PubMed ID: 15964160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term hormone replacement treatment in menopause: new choices, old apprehensions, recent findings.
    Campagnoli C; Lesca L; Cantamessa C; Peris C
    Maturitas; 1993 Dec; 18(1):21-46. PubMed ID: 8107614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.